A protocol of systematic review and meta-analysis of acupuncture for drug resistant epilepsy

Wang, Zeyu; Jiang, Yongcheng; Wang, Zeng-Mian; Ren, Mingyu

doi:10.1097/md.0000000000021073

Cited by 2 publications

(2 citation statements)

References 39 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, AEDs may harm cognitive functional development in newborns ( Moavero et al, 2017 ). Moreover, drug resistance to AEDs is a serious problem during therapy, especially in TLE where drug resistance exceeds 50% ( Wang et al, 2019 ). Therefore, safer and more effective treatments are crucial to alleviate seizures and neuronal injury and decrease the risk of FS developing into epilepsy.…”

Section: Introductionmentioning

confidence: 99%

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups

Cheng,

Zhai,

Yuan

et al. 2023

Front. Cell. Neurosci.

View full text Add to dashboard Cite

BackgroundFebrile seizures (FS) usually occur in childhood and may cause irreversible neuronal damage, cognitive functional defects, and an increase in the risk of epilepsy later in life. Anti-epileptic drugs (AEDs), currently used to treat FS in children, can relieve seizures. However, their effects in preventing the risk of developing epilepsy in later life are unsatisfactory. Moreover, AEDs may damage child brain development. Here, we evaluated the efficiency of xenon in treating prolonged FS (PFS) and preventing epilepsy in Sprague-Dawley pups.MethodsProlonged FS was induced by hyperthermic treatment. After 90 min of PFS, the pups in the xenon treatment group were immediately treated with 70% xenon/21% oxygen/9% nitrogen for 60 min. The levels of glutamate, mitochondrial oxidative stress, mitophagy, and neuronal injury, seizures, learning, and memory functions were measured at specific time points.ResultsNeonatal period PFS led to spontaneous seizure, learning and memory dysfunction, accompanied by increased levels of glutamate, mitochondrial oxidative stress, mitophagy, and neuronal injury. Xenon treatment alleviated the changes caused by PFS and reduced the risk of PFS developing into epilepsy later.ConclusionOur results suggest that xenon inhalation could be a potential therapeutic strategy to attenuate neuronal injury and prevent epilepsy in patients with FS.

show abstract

Section: Introductionmentioning

confidence: 99%

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups

Cheng,

Zhai,

Yuan

et al. 2023

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Uncontrolled seizures remain a significant problem in one third of treated patients 3,4 . Poor responses to ASMs persist despite the abundant availability of antiseizure medications (ASMs) 3–8 . In drug‐resistant patients, the burden of epilepsy is further compounded.…”

Section: Introductionmentioning

confidence: 99%

Real‐world antiseizure medication treatment outcomes in drug‐resistant focal epilepsy patients

Hatoum,

Arcona,

Mao

et al. 2023

Epilepsia Open

View full text Add to dashboard Cite

ObjectiveTo gather real‐world evidence on anti‐seizure medications (ASMs) treatment patterns and related outcomes in patients with drug‐resistant focal epilepsy.MethodsMedical insurance claims from the start of 2014 till end of 2019 were used. Patients selection criteria included ICD codes followed by documented ASM use. Baseline patient demographics along with ASM and rescue medications use patterns and related patients outcome were documented for first (index) ASM regimen. Patients who failed the first regimen and then failed the second regimen were considered drug‐resistant. Multivariate analyses were performed to identify risks and other characteristics for positive or negative treatment outcomes.ResultsStudy cohort consisted of 46,474 patients with mean age of 47.23 (SD:16.94). Levetiracetam was most first‐encountered ASM (37.94%). At baseline, 87.14% were treated with ASMs prior to having study confirmed diagnoses. Mental comorbidities were present in 37.86% of patients. Post first‐year ASM treatment, 34.61% of patients persisted on their index regimen and 5.91% were seizure‐free. Patients failing first ASM regimen numbered 12,868 (27.69%). Drug‐resistant patients who failed first and then second ASM regimens numbered 6,335 (49.23%). Percentages of patients who had successful second treatment, or seizure free were 21.32, and 3.65, respectively.Initiating patients on lamotrigine or carbamazepine (relative to levetiracetam), baseline use of index ASM, rescue medications, older age or male gender, all lowered risk for treatment failure. Having higher comorbidity, co‐morbid mental illness, headache or neoplasty increased such a risk. Baseline use of index ASM, depressive episode or anxiety disorder, all entailed higher risk of failing second ASM treatment.SignificanceOverall, reported findings indicated patient history at baseline, the early selection of an ASM, all influenced treatment outcome. Findings pointed to the complex nature of ASM treatment in drug resistant focal epilepsy patients calling for additional research to identify the optimal treatment to achieve beneficial patient outcomes.

show abstract

A protocol of systematic review and meta-analysis of acupuncture for drug resistant epilepsy

Cited by 2 publications

References 39 publications

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups

Xenon inhalation attenuates neuronal injury and prevents epilepsy in febrile seizure Sprague-Dawley pups

Real‐world antiseizure medication treatment outcomes in drug‐resistant focal epilepsy patients

Contact Info

Product

Resources

About